Todd Foley, M.B.A.
Todd Foley is an experienced biotech investor and executive and serves on a number of MPM portfolio company boards, including Chiasma, CODA Biotherapeutics, Entrada Therapeutics, Iconic Therapeutics, Repare Therapeutics, Rhythm Pharmaceuticals and Tetherex Pharmaceuticals. He previously served on the board of Semma Therapeutics prior to its acquisition by Vertex in late 2019.
Todd also manages MPM’s strategic investment relationship with Novartis, which MPM believes has been one of the industry’s longest standing and most prolific collaborations between venture capital investors and pharma, having committed $200 million to over a dozen companies in the biotech and healthcare IT space under a variety of creative joint equity/strategic deal structures. Prior to MPM, Todd’s career in the life science industry included business development at Genentech (Roche) and management consulting with Arthur D. Little.
Todd earned his M.B.A. from Harvard Business School and his B.S. in Chemistry from the Massachusetts Institute of Technology.